Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17297243 | 0.87 | ALDH1A1 (0.48) | MAPTALDH1A1POLBTDP1HDAC4 | |
| SCHEMBL2067138 | 0.83 | MAPT (0.53) | MAPTALDH1A1POLBTDP1MEN1 | |
| SCHEMBL9925183 | 0.79 | MAPT (0.47) | MAPTALDH1A1POLBTDP1HDAC4 | |
| SCHEMBL2065711 | 0.79 | MAPT (0.47) | MAPTALDH1A1POLBTDP1HDAC4 | |
| SCHEMBL5820588 | 0.74 | LRRK2 (0.51) | MAPTALDH1A1POLBMEN1KMT2A | |
| SCHEMBL458707 | 0.74 | LRRK2 (0.51) | MAPTALDH1A1POLBTDP1MEN1 | |
| SCHEMBL10085220 | 0.74 | LRRK2 (0.51) | MAPTALDH1A1POLBTDP1MEN1 | |
| SCHEMBL30455414 | 0.74 | LRRK2 (0.51) | MAPTALDH1A1POLBTDP1MEN1 | |
| SCHEMBL26384716 | 0.72 | LRRK2 (0.50) | POLBMEN1KMT2ALRRK2IDO1 | |
| SCHEMBL19449866 | 0.72 | LRRK2 (0.57) | MAPTALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199920-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492434-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | Siga Technologies, Inc, (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8148428-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148428-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2007100888-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165493-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
| US-20090036513-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
| US-20120149751-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | GK, ZC3HAV1, GALK1 | MAPT 814/4885ALDH1A1 4066/4885POLB 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.